Cargando…

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma

Tumor biopsies may help to reliably distinguish hepatocellular carcinoma (HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies. Clarifying tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rimassa, Lorenza, Reig, Maria, Abbadessa, Giovanni, Peck-Radosavljevic, Markus, Harris, William, Zagonel, Vittorina, Pastorelli, Davide, Rota Caremoli, Elena, Porta, Camillo, Damjanov, Nevena, Patel, Hitendra, Daniele, Bruno, Lamar, Maria, Schwartz, Brian, Goldberg, Terri, Santoro, Armando, Bruix, Jordi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Letters To The Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385412/ https://www.ncbi.nlm.nih.gov/pubmed/28428725 http://dx.doi.org/10.3748/wjg.v23.i13.2448

Ejemplares similares

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
por: Santoro, A, et al.
Publicado: (2013)

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2017)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
por: Rimassa, Lorenza, et al.
Publicado: (2016)

Caring for Patients with Advanced Stage Cancer at the Time of COVID‐19
por: Brunello, Antonella, et al.
Publicado: (2020)

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments
por: Reig, Maria, et al.
Publicado: (2017)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success
por: Da Fonseca, Leonardo G., et al.
Publicado: (2018)

Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research
por: Negri, Francesca, et al.
Publicado: (2021)

Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma
por: Zustovich, Fable, et al.
Publicado: (2011)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

Novel Therapies for Hepatocellular Carcinoma
por: Rimassa, Lorenza
Publicado: (2020)

Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas
por: Zoccarato, Marco, et al.
Publicado: (2021)

Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature
por: Farina, Patrizia, et al.
Publicado: (2014)

Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience
por: Wattenberg, Max M., et al.
Publicado: (2019)

Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa)
por: Bergamo, Francesca, et al.
Publicado: (2014)

Drug Therapy for Advanced-Stage Liver Cancer
por: Peck-Radosavljevic, Markus
Publicado: (2014)

Editorial
por: Peck-Radosavljevic, Markus
Publicado: (2020)

Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
por: Rimassa, Lorenza, et al.
Publicado: (2020)

Oral ulcer as an exclusive sign of gastric cancer: report of a rare case
por: Colombo, Piergiuseppe, et al.
Publicado: (2005)

Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
por: Olioso, Debora, et al.
Publicado: (2021)

A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

Controversies in the management of hepatocellular carcinoma
por: Forner, Alejandro, et al.
Publicado: (2019)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2020)

Students´ backwardness in extended enrolment. /
por: Cano Escobar, María Fernanda
Publicado: (2018)

Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients
por: Lombardi, Giuseppe, et al.
Publicado: (2019)

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
por: Birzu, Cristina, et al.
Publicado: (2020)

Older cancer patients and COVID‐19 outbreak: Practical considerations and recommendations
por: Brunello, Antonella, et al.
Publicado: (2020)

Review article: systemic treatment of hepatocellular carcinoma
por: Pinter, Matthias, et al.
Publicado: (2018)

COVID-19 trial co-enrolment and subsequent enrolment
por: Gertner, Elie
Publicado: (2020)

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
por: Prete, Alessandra Anna, et al.
Publicado: (2022)

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Current options and future directions of systemic therapy for advanced biliary tract cancer
por: Prete, Maria Giuseppina, et al.
Publicado: (2021)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
por: Campani, Claudia, et al.
Publicado: (2020)

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment
por: Macias, Rocio I. R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d9n5vvsc3p4npltmih8tnjbl8s